Mercator Therapeutics and X-BODY Biosciences Establish Alliance to Generate Antibody Cancer Therapeutics

Published: Jan 06, 2011

(BUSINESS WIRE)--Mercator Therapeutics, Inc., the first biopharmaceutical company to systematically use in vivo phage display technology to develop novel cancer drugs, and X-BODY BioSciences, Inc., a developer of monoclonal antibody therapeutics, today announced a multi-target research collaboration. The companies will collaborate to develop antibodies to four of Mercator’s cancer targets identified using Mercator’s proprietary in vivo screening technology.

Back to news